Sugi Predict

Sugi Predict / Compounds / SCHEMBL634086

SCHEMBL634086

SCHEMBL634086

CC(C)(C)NS(=O)(=O)Cc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 2/20 0.57
▸ CA2 P00918 2/20 0.57
▸ MMP1 P03956 1/20 0.57
▸ MMP2 P08253 1/20 0.57
▸ MMP9 P14780 1/20 0.57
▸ MMP8 P22894 1/20 0.57
▸ MMP13 P45452 1/20 0.57
▸ ALDH1A1 P00352 5/20 0.51
▸ KDM4E B2RXH2 3/20 0.51
▸ HPGD P15428 3/20 0.51
▸ KMT2A Q03164 2/20 0.47
▸ FAAH O00519 1/20 0.47
▸ PRSS1 P07477 1/20 0.47
▸ PRSS2 P07478 1/20 0.47
▸ ELANE P08246 1/20 0.47
▸ PRTN3 P24158 1/20 0.47
▸ PRSS3 P35030 1/20 0.47
▸ CA5A P35218 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5963267 0.82 CA1 (0.55) CA1CA2MMP1MMP2MMP9
SCHEMBL14675961 0.82 CA1 (0.55) CA1CA2MMP1MMP2MMP9
SCHEMBL5012329 0.81 IDO1 (0.54) CA1CA2MMP1MMP8MMP13
SCHEMBL24429451 0.81 KMT2A (0.49) CA1CA2ALDH1A1KDM4EHPGD
SCHEMBL7461728 0.81 CA1 (0.40) CA1CA2MMP1MMP2MMP9
SCHEMBL5963970 0.80 CA1 (0.49) CA1CA2MMP1MMP2MMP9
SCHEMBL20033705 0.80 CA1 (0.49) CA1CA2MMP1MMP2MMP9
SCHEMBL5264576 0.80 CA1 (0.57) CA1CA2MMP1MMP2MMP9
SCHEMBL4436827 0.79 CYP19A1 (0.45) CA1CA2ALDH1A1KDM4EHPGD
SCHEMBL15438998 0.79 CA1 (0.47) CA1CA2MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11136321-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2021-10-05 — — US disclosed
US-20200407361-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2020-12-31 — — US disclosed
US-9938236-B2 Antiviral agents against HBV infection DREXEL UNIVERSITY (US) 2018-04-10 — — US disclosed
US-9938236-B2 Antiviral agents against HBV infection DREXEL UNIVERSITY (US) 2018-04-10 — — US disclosed
US-20180072745-A1 IRE-1alpha INHIBITORS FOSUN ORINOVE PHARMATECH, INC. (CN) 2018-03-15 — — US disclosed
US-20180022752-A1 FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF Shanghai De Novo Pharmatech Co., Ltd. (CN) 2018-01-25 — — US disclosed
US-9867803-B2 IRE-1α inhibitors SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD. (CN) 2018-01-16 — — US disclosed
US-9867803-B2 IRE-1α inhibitors SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD. (CN) 2018-01-16 — — US disclosed
US-9856266-B2 IRE-1alpha inhibitors SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD. (CN) 2018-01-02 — — US disclosed
US-20170326104-A1 IRE-1ALPHA INHIBITORS FOSUN ORINOVE PHARMATECH, INC. (CN) 2017-11-16 — — US disclosed
EP-1904474-A1 NEW PYRIDINE ANALOGUES AstraZeneca AB (SE) 2008-04-02 — — EP disclosed
US-20080045568-A1 Novel high affinity quinoline-based kinase ligands SCHERING CORPORATION 2008-02-21 — — US disclosed
EP-1838687-A1 NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS AstraZeneca AB (SE) 2007-10-03 — — EP disclosed
EP-1838686-A1 DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS AstraZeneca AB (SE) 2007-10-03 — — EP disclosed
WO-2007008140-A1 NEW PYRIDINE ANALOGUES ASTRAZENECA AB (SE) 2007-01-18 — — WO disclosed
WO-2006073366-A1 NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2006-07-13 — — WO disclosed
WO-2006073363-A1 DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2006-07-13 — — WO disclosed
US-5981595-A LOWERS BLOOD CHOLESTEROL LEVELS WARNER-LAMBERT COMPANY (US) 1999-11-09 — — US disclosed
US-5254589-A Anticholesterol agent WARNER-LAMBERT COMPANY (US) 1993-10-19 — — US disclosed
WO-1993008161-A1 SULFONYL UREA AND CARBAMATE ACAT INHIBITORS WARNER-LAMBERT COMPANY (US) 1993-04-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170326104-A1 IRE-1ALPHA INHIBITORS ERN1, XBP1, ERN2 CA1 4157/4885CA2 4153/4885MMP1 2555/4885
US-20180022752-A1 FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF IDO1, IDO2, TDO2 CA1 1754/4885CA2 1563/4885MMP1 1113/4885
US-20180072745-A1 IRE-1alpha INHIBITORS XBP1, ERN1, ATF4 CA1 3761/4885CA2 3135/4885MMP1 2442/4885
US-20080045568-A1 Novel high affinity quinoline-based kinase ligands CDKL2, CDK2, CDKL1 CA1 4279/4885CA2 2837/4885MMP1 3698/4885
US-11136321-B2 Tricyclic compounds SLC10A1, PKD1, CEL CA1 2095/4885CA2 945/4885MMP1 2739/4885
US-20200407361-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL CA1 2095/4885CA2 945/4885MMP1 2739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.